IRON Quote, Financials, Valuation and Earnings

Artiva Biotherapeutics, Inc. has a net margin of -- compared to Disc Medicine, Inc.'s net margin of -5562.95%. Disc Medicine, Inc.'s return on equity of -32.82% beat Artiva Biotherapeutics, Inc.'s return on equity of -47.44%.

Disc Medicine, Inc. has a consensus price target of $121.67, signalling upside risk potential of 53.21%. On the other hand Artiva Biotherapeutics, Inc. has an analysts' consensus of $17.00 which suggests that it could grow by 296.27%. Given that Artiva Biotherapeutics, Inc. has higher upside potential than Disc Medicine, Inc., analysts believe Artiva Biotherapeutics, Inc. is more attractive than Disc Medicine, Inc..

Disc Medicine, Inc. has a beta of 0.870, which suggesting that the stock is 13.012% less volatile than S&P 500. In comparison Artiva Biotherapeutics, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Disc Medicine, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Artiva Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Disc Medicine, Inc. pays -- of its earnings as a dividend. Artiva Biotherapeutics, Inc. pays out -- of its earnings as a dividend.

Disc Medicine, Inc. quarterly revenues are --, which are smaller than Artiva Biotherapeutics, Inc. quarterly revenues of --. Disc Medicine, Inc.'s net income of -$62.3M is lower than Artiva Biotherapeutics, Inc.'s net income of -$21.5M. Notably, Disc Medicine, Inc.'s price-to-earnings ratio is -- while Artiva Biotherapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Disc Medicine, Inc. is -- versus 46.79x for Artiva Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals, Inc. has a net margin of -- compared to Disc Medicine, Inc.'s net margin of 38.89%. Disc Medicine, Inc.'s return on equity of -32.82% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 15.37%.

Disc Medicine, Inc. has a consensus price target of $121.67, signalling upside risk potential of 53.21%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $795.38 which suggests that it could grow by 3.05%. Given that Disc Medicine, Inc. has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe Disc Medicine, Inc. is more attractive than Regeneron Pharmaceuticals, Inc..

Disc Medicine, Inc. has a beta of 0.870, which suggesting that the stock is 13.012% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.390, suggesting its less volatile than the S&P 500 by 60.965%.

Disc Medicine, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.46% to investors and pays a quarterly dividend of $0.88 per share. Disc Medicine, Inc. pays -- of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Disc Medicine, Inc. quarterly revenues are --, which are smaller than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.8B. Disc Medicine, Inc.'s net income of -$62.3M is lower than Regeneron Pharmaceuticals, Inc.'s net income of $1.5B. Notably, Disc Medicine, Inc.'s price-to-earnings ratio is -- while Regeneron Pharmaceuticals, Inc.'s PE ratio is 18.48x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Disc Medicine, Inc. is -- versus 5.97x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Revolution Medicines, Inc. has a net margin of -- compared to Disc Medicine, Inc.'s net margin of --. Disc Medicine, Inc.'s return on equity of -32.82% beat Revolution Medicines, Inc.'s return on equity of -51.27%.

Disc Medicine, Inc. has a consensus price target of $121.67, signalling upside risk potential of 53.21%. On the other hand Revolution Medicines, Inc. has an analysts' consensus of $83.26 which suggests that it could grow by 4.54%. Given that Disc Medicine, Inc. has higher upside potential than Revolution Medicines, Inc., analysts believe Disc Medicine, Inc. is more attractive than Revolution Medicines, Inc..

Disc Medicine, Inc. has a beta of 0.870, which suggesting that the stock is 13.012% less volatile than S&P 500. In comparison Revolution Medicines, Inc. has a beta of 0.990, suggesting its less volatile than the S&P 500 by 1.046%.

Disc Medicine, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Revolution Medicines, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Disc Medicine, Inc. pays -- of its earnings as a dividend. Revolution Medicines, Inc. pays out -- of its earnings as a dividend.

Disc Medicine, Inc. quarterly revenues are --, which are smaller than Revolution Medicines, Inc. quarterly revenues of --. Disc Medicine, Inc.'s net income of -$62.3M is higher than Revolution Medicines, Inc.'s net income of -$305.2M. Notably, Disc Medicine, Inc.'s price-to-earnings ratio is -- while Revolution Medicines, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Disc Medicine, Inc. is -- versus -- for Revolution Medicines, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

STAAR Surgical Co. has a net margin of -- compared to Disc Medicine, Inc.'s net margin of 9.38%. Disc Medicine, Inc.'s return on equity of -32.82% beat STAAR Surgical Co.'s return on equity of -25.83%.

Disc Medicine, Inc. has a consensus price target of $121.67, signalling upside risk potential of 53.21%. On the other hand STAAR Surgical Co. has an analysts' consensus of $26.56 which suggests that it could grow by 15.04%. Given that Disc Medicine, Inc. has higher upside potential than STAAR Surgical Co., analysts believe Disc Medicine, Inc. is more attractive than STAAR Surgical Co..

Disc Medicine, Inc. has a beta of 0.870, which suggesting that the stock is 13.012% less volatile than S&P 500. In comparison STAAR Surgical Co. has a beta of 1.000, suggesting its less volatile than the S&P 500 by 0.048000000000004%.

Disc Medicine, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. STAAR Surgical Co. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Disc Medicine, Inc. pays -- of its earnings as a dividend. STAAR Surgical Co. pays out -- of its earnings as a dividend.

Disc Medicine, Inc. quarterly revenues are --, which are smaller than STAAR Surgical Co. quarterly revenues of $94.7M. Disc Medicine, Inc.'s net income of -$62.3M is lower than STAAR Surgical Co.'s net income of $8.9M. Notably, Disc Medicine, Inc.'s price-to-earnings ratio is -- while STAAR Surgical Co.'s PE ratio is 49.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Disc Medicine, Inc. is -- versus 4.97x for STAAR Surgical Co.. Usually stocks with elevated PS ratios are considered overvalued.